How did Senores' revenue and profit perform in Q1 FY27?

Revenue grew 36% YoY to ₹180.21 crore and net profit rose 56% to ₹31 crore. EBITDA jumped 87% to ₹54 crore, reflecting scale benefits.

Was the growth surprising or expected?

The growth was strong but expected. The results were consistent with the company's guidance, making the announcement routine.

What does the appointment of Anjali Shah as senior management mean?

It is a routine governance update. No further details on her role were disclosed in the filing.

How is the stock valued relative to these results?

Senores has a market cap of ₹5,840 crore and a trailing P/E of 50.6x. The current earnings growth supports the high multiple, but any slowdown could pressure valuation.

Earnings · Pharmaceuticals · Mid cap

Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance

Strong growth but priced in. EBITDA margin expanded to nearly 30%. Anjali Shah appointed as senior management.

— 5 earlier stories on Senores Pharmaceuticals Ltd. →

SENORES By Tipsheet Editorial 27 Jul 2026 · 3:35 PM IST Verify on BSE · NSE

Mkt cap₹5,840 cr

P/E50.62×

ROE7.45%

Debt / eq.0.39

₹180.21 cr Q1 FY27 revenue, up 36% YoY

What's new

Revenue rose 36% YoY to ₹180.21 crore
EBITDA surged 87% to ₹54 crore; net profit up 56% to ₹31 crore
Anjali Shah appointed as senior management personnel

Why this matters

The results confirm Senores' growth trajectory but were widely expected given prior guidance. With a trailing P/E of 50x, the valuation already reflects the momentum. The open question is whether the 30% EBITDA margin is sustainable.

What we're watching

Whether revenue growth can sustain above 30%
EBITDA margin trajectory from the current ~30%
Any new product launches or regulatory updates

The full read

Senores Pharmaceuticals delivered a solid Q1 FY27. Revenue rose 36% YoY to ₹180.21 crore, net profit climbed 56% to ₹31 crore. EBITDA surged 87% to ₹54 crore, pushing the margin toward 30% — a sign of scale benefits. The company also named Anjali Shah to senior management, a routine update. These numbers matched guidance, so the filing adds nothing new. The stock's 50x trailing P/E already prices in the trajectory. The open question is whether the 30% EBITDA margin is sustainable or a low-base effect. Three more quarters will answer that.

Questions answered

How did Senores' revenue and profit perform in Q1 FY27?: Revenue grew 36% YoY to ₹180.21 crore and net profit rose 56% to ₹31 crore. EBITDA jumped 87% to ₹54 crore, reflecting scale benefits.
Was the growth surprising or expected?: The growth was strong but expected. The results were consistent with the company's guidance, making the announcement routine.
What does the appointment of Anjali Shah as senior management mean?: It is a routine governance update. No further details on her role were disclosed in the filing.
How is the stock valued relative to these results?: Senores has a market cap of ₹5,840 crore and a trailing P/E of 50.6x. The current earnings growth supports the high multiple, but any slowdown could pressure valuation.

Mentioned: Anjali Shah

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on SENORES →

27 Jul 2026 · 3:35 PM IST Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance
today Senores Pharma targets 50-60% PAT growth after Q1 beat
today Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
today Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
today Senores Q1 profit rises 56% on regulated markets growth